A Phase 2b Multicenter Dose-Ranging Study Evaluating the Safety and Efficacy of a Long-acting Intravitreal Sunitinib Malate Depot Formulation (GB-102) Compared to Intravitreal Aflibercept in Subjects with Neovascular (Wet) Age-related Macular Degeneratio

Project: Other project

StatusActive
Effective start/end date8/21/198/20/23

Funding

  • Syneos Health LLC: $7,403.85